ONCLIVE NEWS NETWORK: ON LOCATION WILL BE LIVE AT ESMO THIS WEEK - STAY TUNED FOR MORE INFORMATION!

Search Videos by Topic or Participant
Browse by Series:

Optimal Treatment Sequencing for Advanced Prostate Cancer

Panelists: Mark S. Austenfeld, MD, Kansas City Urology Care; Raoul S. Concepcion, MD, Urology Associates, PC; E. David Crawford, MD, University of Colorado;
Published: Thursday, Sep 13, 2012


Moderator Raoul S. Concepcion, MD, explains that the multitude of newly approved therapeutics for metastatic and advanced prostate cancer are fitting nicely into urology practices. However, the question facing many physicians is how to sequence these new therapies.

Paul R. Sieber, MD, believes that it may take a decade before reliable evidence-based information is available on sequencing. Additionally, he questions the future role of cytotoxic therapies, as newer and less toxic options become available.

Rudimentarily Sieber's practice has pushed the use of sipuleucel-T (Provenge) earlier in the treatment paradigm. Following this treatment, many physicians are using abiraterone acetate (Zytiga) in the prechemotherapy space with the possibility of also administering enzalutamide (Xtandi) in the future. Additionally, throughout the course of these treatments the management of skeletal-related events can easily be accomplished using denosumab (Xgeva) and zoledronic acid (Zometa). However, Sieber believes that the role cytotoxic agents play is still largely unclear.
Slider Left
Slider Right


Moderator Raoul S. Concepcion, MD, explains that the multitude of newly approved therapeutics for metastatic and advanced prostate cancer are fitting nicely into urology practices. However, the question facing many physicians is how to sequence these new therapies.

Paul R. Sieber, MD, believes that it may take a decade before reliable evidence-based information is available on sequencing. Additionally, he questions the future role of cytotoxic therapies, as newer and less toxic options become available.

Rudimentarily Sieber's practice has pushed the use of sipuleucel-T (Provenge) earlier in the treatment paradigm. Following this treatment, many physicians are using abiraterone acetate (Zytiga) in the prechemotherapy space with the possibility of also administering enzalutamide (Xtandi) in the future. Additionally, throughout the course of these treatments the management of skeletal-related events can easily be accomplished using denosumab (Xgeva) and zoledronic acid (Zometa). However, Sieber believes that the role cytotoxic agents play is still largely unclear.
View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x